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Abstract
The complement cascade plays a role in synaptic pruning and synaptic plasticity, which seem to be involved in cognitive functions and psychiatric disorders.
Genetic variants in the closely related CSMD1 and CSMD2 genes, which are implicated in complement regulation, are associated with schizophrenia. Since patients with schizophrenia often show cognitive impairments, we tested whether variants in CSMD1 and CSMD2 are also associated with cognitive functions per se. We took a discovery-replication approach, using wellcharacterized Scandinavian cohorts. A total of 1637 SNPs in CSMD1 and 206
SNPs in CSMD2 were tested for association with cognitive functions in the NCNG sample (Norwegian Cognitive NeuroGenetics; n=670). Replication testing of SNPs with p-value < 0.001 (7 in CSMD1 and 3 in CSMD2) was carried out in the TOP sample (Thematically Organized Psychosis; n=1025) and the BETULA sample (Betula Longitudinal Study on aging, memory and dementia; n=1742).
Finally, we conducted a meta-analysis of these SNPs using all three samples. The previously identified schizophrenia marker in CSMD1 (SNP rs10503253) was also included. The strongest association was observed between the CSMD1 SNP rs2740931 and performance in immediate episodic memory (p-value = 5x10 -6 , minor allele A, MAF 0.48-0.49, negative direction of effect). This association reached the study-wide significance level (p ≤ 1.2x10 -5 ). SNP rs10503253 was not significantly associated with cognitive functions in our samples. In conclusion, we studied n=3,437 individuals and found evidence that a variant in CSMD1 is associated with cognitive function. Additional studies of larger samples with cognitive phenotypes will be needed to further clarify the role of CSMD1 in cognitive phenotypes in health and disease.
Introduction
Schizophrenia is a severe mental disorder which creates a considerable burden for the patients, their families and society (1, 2) . In many patients, deficits in certain aspects of cognitive function have been observed (3) . The heritability of schizophrenia is high (up to 75% (4)). In the last decade many genetic variants implicated in schizophrenia have been identified (5) (6) (7) (8) , leading to a better understanding of the complexity of its genetic architecture. Recent studies have also shown that the genetic variants that are implicated in schizophrenia can influence cognitive abilities (9) (10) (11) (12) (13) . Follow-up studies to determine the effect of these genes on cognitive functions may help us to understand the effect of genetic factors on cognitive dysfunction in schizophrenia, and vice versa. Recent genetic findings have implicated several biological pathways in schizophrenia, e.g. synaptic plasticity, the immune system and histone modifications (14).
Synaptic plasticity is the ability of synapses to change over time. Several mechanisms are involved in synaptic plasticity, such as long-term potentiation, long-term depression and synaptic pruning. Synaptic pruning is the removal of unused synapses and is thought to be especially important for cognitive processes in the developing brain (15) . The complement system, which plays a crucial role in the defense against pathogens in the immune system, is also involved in synaptic pruning (16) . It has been demonstrated that the complement cascade directs the tagging of obsolete synapses and their subsequent removal by microglial cells (17) . Pruning is essential for the development of the brain and of complex cognitive processes such as learning. In a rat model of synaptic plasticity, we observed up-regulation of several genes of the complement cascade following induction of long-term potentiation in the hippocampus (18) . We subsequently performed a case-control association study to test genes of the complement cascade for their potential effect as genetic factors in schizophrenia. The strongest associations were observed for genetic variants located in the CSMD1 and CSMD2 genes (CUB and Sushi multiple domains 1, and CUB and Sushi multiple domains 2) (19) . In a complementary hypothesis-free approach, the Psychiatric Genomics Consortium tested the whole genome for association (i.e. in a genome-wide association study, GWAS) with schizophrenia and identified, among other loci, additional variants located in CSMD1 that were associated with schizophrenia (6, 20) .
CSMD1 (OMIM ID 608397; 8p23.2) and CSMD2 (OMIM ID 608398; 1p35.1) are described as regulators of complement activation and inflammation in the developing central nervous system (21) . Complement activation is gaining much attention because it is essential for synaptic plasticity and has recently been implicated in several brain-related conditions like schizophrenia (22) and Alzh ' d (23) . These findings have prompted further investigations of the CSMD1 variant rs10503253, which is the SNP that showed the strongest association with schizophrenia in the PGC GWAS. Indeed, association has been reported between rs10503253 and several cognitive variables (24, 25) . Here, we tested genetic variants covering the whole CSMD1 and CSMD2 genes for association with cognitive abilities in three independent samples.
Methods and Materials
The study utilizes a discovery-replication design. Data are first extracted from the discovery sample (NCNG, N=670) by genome wide genotyping, then tested for replication in two independent Scandinavian samples (BETULA, N=1700 and TOP, N= 1025). A summary of the cohorts, the markers typed and the phenotypes analyzed is provided in Table 1 . Informed consent was obtained from all participants.
NCNG Sample
The NCNG (Norwegian Cognitive NeuroGenetics) sample, described fully in 
BETULA Sample
The Betula Project is a longitudinal study, started in 1988, on aging, memory, and dementia (33) . This sample consists of individuals that have been assessed for cognitive functions of memory, speed of processing, and attention. All participants signed informed consent, in accordance with the guidelines of the Swedish Council for Research in Humanities and Social Sciences. The measures of cognitive function used here were selected to allow comparison with the NCNG sample (see Table 1 We used a subset of 1,800 BETULA samples for which DNA was available.
Samples were genotyped for 3 markers in the CSMD2 gene, and 8 markers in the CSMD1 gene, which were selected due to their association in the NCNG sample.
Genotyping was done with a custom Illumina Infinium iSelect custom design array (http://www.illumina.com). Samples were subjected to stringent quality control in PLINK (34) . SNPs were excluded from the analysis if they had a genotype success rate < 0.95, MAF < 0.01, or HWE exact test P < 0.001. After quality control of the iSelect genotyping data, 1,742 individuals remained.
It should be noted that while the NCNG and TOP samples were filtered for cryptic relatedness and population structure, the BETULA sample used in this study was genotyped for fewer markers and thus could not be filtered for these parameters.
TOP Sample
Participants were recruited as part of a large ongoing study on schizophrenia and bipolar disorder, the Thematic Organized Psychosis Research (TOP) Study, which is run by Oslo University Hospital, Norway (35, 36) . The healthy participants were randomly selected from national statistical records from the same catchment area and contacted by letter inviting them to participate. The healthy sample was screened by interview for symptoms of severe mental illness and with the Primary Care Evaluation of Mental Disorders (PRIME-MD) (37), and subjects were excluded if they or any close relatives had a history of a severe psychiatric disorder (schizophrenia, bipolar disorder and major depression), or substance abuse or dependency in the last three months. Exclusion criteria for all groups were: IQ score below 70, hospitalized head injury, neurological disorder, (42) . Genotypes for the 11 markers (8 in CSMD1 and 3 in CSMD2) selected from the association data in the NCNG sample, were extracted from the imputed TOP dataset.
Association Analyses
The association of the SNPs with cognitive phenotypes was tested using linear regression performed in PLINK (34) . Age and sex were set as covariates except for the IQ measure, which had already been adjusted for age. In the TOP sample, since we used cases and controls, the diagnosis was also included as a covariate.
In addition, all the markers were tested for association in cases versus controls, but none showed any significance (min p-value 0.41).
The meta-analyses were performed for each trait using the inverse variance weighted model from the METAL software package (43) , and overall measures of association were obtained.
We calculated the study-wide significance levels using PLINK to produce the correlation matrices and Nyhol ' M SpDl (http://neurogenetics.qimrberghofer.edu.au/matSpDlite/) to determine the effective number of SNPs (44), and thus the study-wide correction threshold with the method of Li et al (45) . For the overall study (CSMD1 and CSMD2), the correlation matrix estimated that the total number of independent tests was 853, meaning a significance threshold at 6x10 -5 . Using the same method to calculate the matrix correlation between the traits tested, we estimated that the effective Number of Independent Variables (VeffLi) was five, thus leading to a study-wide threshold value of 1.2 x 10 -5 .
Results
The genomic organization of CSMD1 and CDM2 is shown in Supplementary   Figure 1 . In the NCNG sample, 1637 and 206 SNP variants located in CSMD1 and
CSMD2, respectively, were tested for association with 6 cognitive measures using linear regression corrected for age and gender (full results are given in Supplementary Table 2 ). We also included the CSMD1 marker rs10503253, which was associated with schizophrenia in the PGC study (6) , to test it for association in a meta-analysis of all three samples. In the BETULA sample, one marker (rs756094 in CSMD1)
failed genotyping in an Illumina INFINIUM iSelect assay, while for the TOP sample, the genotypes for all the markers were used (see Supplementary Tables   3 and 4 for results in the BETULA and TOP samples respectively). Tables 2-4 show the meta-analysis results for the selected markers across the 6 traits. The strongest association was observed for rs2740931 in CSMD1 (p-value = 5x10 -6 , minor allele A, MAF 0.48-0.49) with immediate episodic memory ( Table   2 and Supplementary Table 5 ). This passed the study-wide significance threshold of p ≤ 1.2x10 -5 , as calculated using a correction based on the effective number of markers and traits tested (44, 45) . The association of rs2740931 with immediate episodic memory was further strengthened by the observation that all 3 samples show association with the same direction of effect, and the association was nominally significant in 2 of the 3 samples (NCNG p = 0.0007; BETULA p = 0.0008). Other nominally significant associations were observed but did not reach study-wide significance.
For the schizophrenia-associated marker rs10503253 in CSMD1, we did not observe any significant association across samples at the genome-wide or studywide level. There was nominally significant association (p-value = 0.007;  = 0.67 for A allele; see Supplementary Tables 1 and 2 ) between this variant and matrix reasoning in the NCNG sample.
Discussion
Here we have tested genetic variants located in the CSMD1 and CSMD2 genes for their association with tasks representing several cognitive function domains. We found study-wide significant association between a genetic variant in the CSMD1 gene (rs2740931) and immediate episodic memory. We did not find significant association between cognitive abilities and rs10503253, which was the main signal of association between CSMD1 and schizophrenia (6).
In our study, we investigated the entire CSMD1 and CSMD2 genes, an approach that has advantages and disadvantages. The main disadvantage was that by testing more markers, we increased the risk of type 1 errors. This is especially true for larger genes, such as CSMD1 (2.0 MB) and CSMD2 (0.7 MB), which are more prone to variation than small genes. By the same token, however, larger genes are also more susceptible to functional variation. Thus, this gene-based approach has the advantage of allowing for allelic heterogeneity within and between the traits to be tested (46 shown that the complement-mediated clearing of synapses by microglia might be defective (23) . It was shown recently that the strongest association with schizophrenia observed by the PGC GWAS could be attributed to a variation in the number of copies of the complement C4 gene, which mediates synapse elimination during postnatal development (22) . CSMD1 promotes the degradation of the activated complement proteins C3b and C4b (60), although further work is needed to demonstrate how this affects synaptic pruning. It is now clear that the complement cascade plays an important role in synaptic pruning and is implicated in many traits that are dependent on synaptic plasticity, including cognitive functions and psychiatric and neurodegenerative disorders. As neuroimmunological studies are beginning to implicate the immune system in cognitive functions and dysfunctions, it will be interesting in the future to test whether immune markers and biomarkers may be related to cognition, We could not perform such an analysis with the data available to us here.
The SNP associated in our study, rs2740931, is located in intron 4 of the long transcript of CSMD1 near a region that is transcribed but not translated in the variants.
An advantage of our study is that it contains only Scandinavian samples, which increases the homogeneity and thus the chance to identify genetic association (65) ; however, our study is still limited compared to the large sample sizes that genetic consortia can obtain. Until now, large multi-center meta-analyses of GWAS have been reported only for general cognitive abilities (e.g. from the CHARGE (66) or the COGENT (10) consortia), verbal declarative memory delayed recall (67) and executive functioning -speed of processing (68) . We will probably have to wait until other consortia gather large samples phenotyped for additional cognitive abilities to cover a larger range of domains. However, another major challenge when collecting large samples to identify genes implicated in cognitive abilities, which is also a limitation of our study, is the reliability with which the phenotype can be compared across samples. genetic profiles might underlie specific processes of human episodic memory (71) . This supports the current efforts of consortia to perform large GWAS on a wider range of cognitive phenotypes.
Conclusion
We have presented evidence that a variant in CSMD1 is associated with cognitive function. It is an exciting time for genetic studies of cognition and mental disorders, because biological mechanisms are being revealed which will help to prove or refute old biological hypotheses. However, it is also a challenging time, because we are only beginning to understand the breadth of the multidimensional complexity of the genetic (and epigenetic) mechanisms that account for inter-individual variability in brain function. In due course, larger-scale studies will help solve these problems. Table 3 . Meta-analysis of the association of CSMD1 and CSMD2 SNPs with processing speed and visuospatial ability. For details, see Table 2 . Table 4 . Meta-analysis of the association of CSMD1 and CSMD2 SNPs with semantic knowledge and IQ. For details, see Table 2 . 
